MwanzoBNTX • NASDAQ
add
BioNTech SE
Bei iliyotangulia
$ 109.26
Bei za siku
$ 109.43 - $ 111.07
Bei za mwaka
$ 79.88 - $ 131.49
Thamani ya kampuni katika soko
26.50B USD
Wastani wa hisa zilizouzwa
elfu 680.64
Uwiano wa bei na mapato
-
Mgao wa faida
-
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 260.80M | 102.64% |
Matumizi ya uendeshaji wa biashara | 621.10M | -39.74% |
Mapato halisi | -386.60M | 52.14% |
Kiwango cha faida halisi | -148.24 | 76.38% |
Mapato kwa kila hisa | -1.60 | 52.38% |
EBITDA | -385.70M | 57.70% |
Asilimia ya kodi ya mapato | 4.00% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 14.04B | -18.84% |
Jumla ya mali | 21.64B | -2.70% |
Jumla ya dhima | 3.13B | -1.05% |
Jumla ya hisa | 18.51B | — |
hisa zilizosalia | 240.40M | — |
Uwiano wa bei na thamani | — | — |
Faida inayotokana na mali | -5.10% | — |
Faida inayotokana mtaji | — | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -386.60M | 52.14% |
Pesa kutokana na shughuli | — | — |
Pesa kutokana na uwekezaji | -64.40M | 73.32% |
Pesa kutokana na ufadhili | -13.30M | 41.92% |
Mabadiliko halisi ya pesa taslimu | — | — |
Mtiririko huru wa pesa | -292.96M | -116.69% |
Kuhusu
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2008
Tovuti
Wafanyakazi
6,772
